Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Catabasis Has The Potential To Provide Edasalonexent As Treatment For The Entire DMD Population Not Just A Subset Of It

6h seekingalpha
The positive phase 2 results observed in DMD patients, along with the initiation of the phase 3 trial soon should value Catabasis with a higher market cap. (56-0)

SRPT / Sarepta Therapeutics, Inc. / Point72 Asset Management, L.P. - AMENDMENT NO. 1 (Passive Investment)

2018-02-16 sec.gov
240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Sarepta Therapeutics, Inc. (Title of Class of Securities) Common Stock, Par Value $0.0001 Per Share (CUSIP Number) 803607100 (Date of Event Which Requires Filing of this Statement) Dece

SRPT / Sarepta Therapeutics, Inc. / Tourbillon Capital Partners, L.P. - FEBRUARY 14, 2018 (Passive Investment)

2018-02-16 sec.gov
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C.  20549 SCHEDULE 13G (RULE 13D - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 2)* Sarepta Therapeutics, Inc. (Name of Issuer) Common Stock with $0.0001 par value (Title of Class of Securities) 803607100 (CUSIP Number) December 31, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pur

SRPT / Sarepta Therapeutics, Inc. / Point72 Asset Management, L.P. - AMENDMENT NO. 1 (Passive Investment)

2018-02-16 sec.gov
240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Sarepta Therapeutics, Inc. (Title of Class of Securities) Common Stock, Par Value $0.0001 Per Share (CUSIP Number) 803607100 (Date of Event Which Requires Filing of this Statement) Dece

SRPT / Sarepta Therapeutics, Inc. / Tourbillon Capital Partners, L.P. - FEBRUARY 14, 2018 (Passive Investment)

2018-02-16 sec.gov
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C.  20549 SCHEDULE 13G (RULE 13D - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 2)* Sarepta Therapeutics, Inc. (Name of Issuer) Common Stock with $0.0001 par value (Title of Class of Securities) 803607100 (CUSIP Number) December 31, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pur

Solid Biosciences: Initiating Coverage With A Sell Rating And First Price Target Of $18

2018-02-14 seekingalpha
We are unable to justify the current market cap of $876M for Solid Biosciences, considering competition from Sarepta Therapeutics and Pfizer (even in our bull valuation scenario). (21-1)

SRPT / Sarepta Therapeutics, Inc. / VANGUARD GROUP INC - 3G/A (Passive Investment)

2018-02-14 sec.gov
sareptatherapeuticsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 4 )*       Name of issuer:  Sarepta Therapeutics Inc     Title of Class of Securities:  Common Stock     CUSIP Number:  803607100     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule is file

SRPT / Sarepta Therapeutics, Inc. / FMR LLC / Fidelity - 3G/A (Passive Investment)

2018-02-14 sec.gov
SCHEDULE 13G Amendment No. 1 SAREPTA THERAPEUTICS INC COMMON STOCK Cusip #803607100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #803607100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 1,998,470 Item 6: 0 Item 7: 7,760,905 Item 8: 0 Item 9: 7,760,905 Item 11: 11.

SRPT / Sarepta Therapeutics, Inc. / FMR LLC / Fidelity - 3G/A (Passive Investment)

2018-02-14 sec.gov
SCHEDULE 13G Amendment No. 1 SAREPTA THERAPEUTICS INC COMMON STOCK Cusip #803607100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #803607100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 1,998,470 Item 6: 0 Item 7: 7,760,905 Item 8: 0 Item 9: 7,760,905 Item 11: 11.

SRPT / Sarepta Therapeutics, Inc. / VANGUARD GROUP INC - 3G/A (Passive Investment)

2018-02-14 sec.gov
sareptatherapeuticsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 4 )*       Name of issuer:  Sarepta Therapeutics Inc     Title of Class of Securities:  Common Stock     CUSIP Number:  803607100     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule is file

Sarepta Therapeutics: Doubling Down On The Pullback

2018-02-13 seekingalpha
Golodirsen's Essence study scare, along with a market-wide pullback, present a very tempting buying point when the fundamentals are as good as they have ever been. (19-0)

Your Daily Pharma Scoop: GW Pharmaceuticals Pullback, Seattle Genetics Announces Collaboration Agreement, Catalyst Reports Data

2018-02-10 seekingalpha
Today we will discuss GW Pharmaceuticals (GWPH), which after a solid run over the past six months has seen a sharp pullback in its shares during the recent sell-off in the broader market. (140-3)

Why Sarepta Therapeutics Inc Stock is Sliding Today

2018-02-09 investorplace
Sarepta Therapeutics Inc (NASDAQ:SRPT) stock was hit hard today after reports claim one of its studies was put on hold. (19-0)

SRPT / Sarepta Therapeutics, Inc. / SUSQUEHANNA SECURITIES - SC 13G/A (Passive Investment)

2018-02-09 sec.gov
    SECURITIES AND EXCHANGE COMMISSION     Washington, D.C. 20549       SCHEDULE 13G   (Rule 13d-102)   INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2.   (Amendment No. 1)*   Sarepta Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 803607100 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the approp

SRPT / Sarepta Therapeutics, Inc. / SUSQUEHANNA SECURITIES - SC 13G/A (Passive Investment)

2018-02-09 sec.gov
    SECURITIES AND EXCHANGE COMMISSION     Washington, D.C. 20549       SCHEDULE 13G   (Rule 13d-102)   INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2.   (Amendment No. 1)*   Sarepta Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 803607100 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the approp


CUSIP: 803607100